血清质谱法用于接受ARI0002h CAR T细胞治疗的多发性骨髓瘤患者的治疗监测
研究纳入33例接受BCMA靶向CAR T细胞ARI0002h(Cesnicabtagene Autoleucel)治疗的复发/难治多发性骨髓瘤患者,评估定量免疫沉淀质谱法(QIP-MS)在治疗监测中的表现。QIP-MS较血清免疫固定电泳(sIFE)提供更详细信息,可识别糖基化M蛋白和微小附加峰,并成功检测达雷妥尤单抗或托珠单抗治疗的潜在干扰。QIP-MS与sIFE总体一致性高(78.8%),与骨髓下一代流式细胞术(NGF)仅中等一致(55.6%),且在各时间点持续显示最低阴性率(第1个月27.3% vs 第12个月60.0%)。
要点
- QIP-MS较sIFE提供更详细M蛋白信息,可识别糖基化M蛋白和微小附加峰。
- QIP-MS成功检测达雷妥尤单抗或托珠单抗治疗导致的潜在干扰。
- QIP-MS与sIFE总体一致性高(78.8%),与骨髓NGF仅中等一致(55.6%)。
核心结论
- QIP-MS作为无创技术在评估多发性骨髓瘤CAR T细胞治疗后反应方面可能特别有用。
研究设计与样本
- 研究纳入33例接受学术型BCMA靶向CAR T细胞ARI0002h(Cesnicabtagene Autoleucel)治疗的复发/难治多发性骨髓瘤患者,评估QIP-MS在治疗监测中的表现。
主要发现
- QIP-MS较sIFE提供更详细信息,可识别糖基化M蛋白和微小附加峰。
- QIP-MS成功检测达雷妥尤单抗或托珠单抗治疗导致的潜在干扰。
- QIP-MS与sIFE总体一致性高(78.8%),与骨髓NGF仅中等一致(55.6%)。
- QIP-MS在各时间点持续显示最低阴性率(第1个月27.3% vs 第12个月60.0%)。
- QIP-MS(+)/骨髓NGF(-)患者的中位无进展生存期较QIP-MS(-)/骨髓NGF(-)患者短,但无统计学显著性。
关键数值与推荐
- QIP-MS与sIFE总体一致性为78.8%。
- QIP-MS与骨髓NGF一致性为55.6%。
- QIP-MS阴性率第1个月为27.3%,第12个月为60.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapies have increased the patients with relapsed/refractory multiple myeloma (RRMM) in whom standard electrophoretic techniques fail to detect the M-protein. Quantitative immunoprecipitation mass spectrometry (QIP-MS) can accurately measure serum M-protein with high sensitivity, and identify interferences caused by therapeutic monoclonal antibodies. Here, we investigate the outcome of QIP-MS in 33 patients treated with the academic BCMA-directed CAR T-cell ARI0002h (Cesnicabtagene Autoleucel). QIP-MS offered more detailed insights than serum immunofixation (sIFE), identifying glycosylated M-proteins and minor additional peaks. Moreover, the potential interferences owing to daratumumab or tocilizumab treatments were successfully detected. When analysing different assay platforms during patient's monitoring after ARI0002h administration, we observed that QIP-MS showed a high global concordance (78.8%) with sIFE, whereas it was only moderate (55.6%) with bone marrow (BM)-based next-generation flow cytometry (NGF). Furthermore, QIP-MS consistently demonstrated the lowest negativity rate across the different timepoints (27.3% vs. 60.0% in months 1 and 12, respectively). Patients with QIP-MS(+)/BM-based NGF(-) showed a non-significant shorter median progression free survival than those with QIP-MS(-)/BM-based NGF(-). In summary, we show the first experience to our knowledge demonstrating that QIP-MS could be particularly useful as a non-invasive technique when evaluating response after CAR T-cell treatment in MM.
引用
- Ortiz de Landazuri I, Oliver-Caldés A, Español-Rego M, et al. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells. Br J Haematol. 2024. PMID: 38894496. doi:10.1111/bjh.19589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。